E. Merck KG, which combines the financial interests of the Merck family and is general partner of Germany’s Merck KGaA (MRK: DE) with an interest of 70%, announced at this year's General Partners' Meeting, the family partners elected their representatives to the Family Board, which is the supervisory body of E. Merck KG.
Frank Stangenberg-Haverkamp, 65, has been elected as the new Chairman of the 12-member Family Board. Jon Baumhauer, 69, previously Chairman of the Family Board and Chairman of the Executive Board of E. Merck KG, has retired from his offices.
Mr Stangenberg-Haverkamp said: “For decades, Jon Baumhauer has uniquely shaped and successfully led the company and the Merck family of owners. The partners are exceptionally grateful to him for his leadership of the community of family members and for familiarizing the next generation with the company.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze